FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsStream2Sea, LLC
FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
Medium -
DrugsHappy Farm Botanicals, Inc.
Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.
High risk -
DrugsPReye, LLC
FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.
High risk -
DrugsSafrel Pharmaceuticals LLC
FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
High risk -
DrugsABS Corporation
ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
High risk -
DrugsAHC Products, Inc.
AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk